🔗 Share this article Patients Stopping Anti-Obesity Medications Gain Back Weight Far More Rapidly Than People Using Diet and Exercise Weight management involves long-term strategies. Fresh analysis reveals that people who stop using new weight-loss injections like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who end conventional lifestyle programs. Findings released in a prominent medical journal demonstrates that while obese people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month upon discontinuation. "Individuals purchasing such drugs should be informed of the danger of quick weight regain when the medication is stopped," stated researcher Dr. Susan Jebb. This pace of recovery means a reversion to pre-treatment weight within about a year and a half. Analyzing Approaches The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods. Researchers point out that individuals who lose weight through dieting typically see a more gradual weight regain—around 100 grams monthly—once they finish. The Reason for the Fast Rebound Doctors believe the mode of action of the drugs explains the amplified rebound. These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely." A Lifelong Disease? Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes. A number of clinicians contend that, given the significant potential of weight regain, the therapy should be considered long-term. This perspective is reinforced by drug manufacturers, who say that the results "emphasize the persistent character of excess weight," akin to managing conditions like diabetes. Patient Testimonies People who have discontinued the medication explain a sudden return of cravings. "It was like a switch activating and you're instantly ravenous," described one woman. This challenge is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment. Widespread Interest Survey data show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Use is more common among women compared to men. The middle-aged age group shows the greatest level of interest. Many obtain the drugs through private healthcare rather than public health services. Ultimately, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated behavioural support.
Weight management involves long-term strategies. Fresh analysis reveals that people who stop using new weight-loss injections like Wegovy and Mounjaro tend to recover shed pounds much more quickly than those who end conventional lifestyle programs. Findings released in a prominent medical journal demonstrates that while obese people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month upon discontinuation. "Individuals purchasing such drugs should be informed of the danger of quick weight regain when the medication is stopped," stated researcher Dr. Susan Jebb. This pace of recovery means a reversion to pre-treatment weight within about a year and a half. Analyzing Approaches The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods. Researchers point out that individuals who lose weight through dieting typically see a more gradual weight regain—around 100 grams monthly—once they finish. The Reason for the Fast Rebound Doctors believe the mode of action of the drugs explains the amplified rebound. These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely." A Lifelong Disease? Medical guidelines recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes. A number of clinicians contend that, given the significant potential of weight regain, the therapy should be considered long-term. This perspective is reinforced by drug manufacturers, who say that the results "emphasize the persistent character of excess weight," akin to managing conditions like diabetes. Patient Testimonies People who have discontinued the medication explain a sudden return of cravings. "It was like a switch activating and you're instantly ravenous," described one woman. This challenge is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment. Widespread Interest Survey data show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow. Use is more common among women compared to men. The middle-aged age group shows the greatest level of interest. Many obtain the drugs through private healthcare rather than public health services. Ultimately, researchers caution that while the jabs are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated behavioural support.